Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CERo Therapeutics HoldingsCERO -9.50% Equity-to-Asset is -16.06 as of Jun. 2026. The stock has 2 warning signs investors should review. Among 1,416 Biotechnology companies, CERo Therapeutics Holdings ranks worse than 97.25% on this metric.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
CERo Therapeutics Holdings Equity-to-Asset Related Terms
CERo Therapeutics Holdings Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CERO vs PTIX, CYTOF, CARM: Equity-to-Asset Comparison
For the Biotechnology subindustry, CERo Therapeutics Holdings's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CERo Therapeutics Holdings Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CERo Therapeutics Holdings's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where CERo Therapeutics Holdings's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
CERo Therapeutics Holdings's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CERo Therapeutics Holdings (CERO) has a Equity-to-Asset of -16.06 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on CERo Therapeutics Holdings and its competitors. According to the industry distribution chart, CERo Therapeutics Holdings ranks #1377 out of 1416 companies in the Biotechnology industry, placing it in the top 97.2%.
Is CERo Therapeutics Holdings' Equity-to-Asset too high?
CERo Therapeutics Holdings' current Equity-to-Asset is -16.06. Based on the distribution chart, CERo Therapeutics Holdings ranks #1377 out of 1416 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does CERo Therapeutics Holdings' Equity-to-Asset compare to PTIX and CYTOF?
According to the Biotechnology industry distribution chart, CERo Therapeutics Holdings ranks #1377 out of 1416 companies for Equity-to-Asset. This places CERo Therapeutics Holdings in the lower half of its industry. The industry median Equity-to-Asset is 0.68. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on CERo Therapeutics Holdings and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CERo Therapeutics Holdings's current Equity-to-Asset is -16.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CERo Therapeutics Holdings stock overvalued right now?
CERo Therapeutics Holdings (CERO) has a current Equity-to-Asset of -16.06. The current Equity-to-Asset is -16.06. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For CERo Therapeutics Holdings (CERO), the current Equity-to-Asset is -16.06 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CERo Therapeutics Holdings Inc is an immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. The company's molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CERO has been successfully added to your 
